Moreover, oncolytic virotherapy (OAV-DEC), another novel therapy, can be combined with CA IX-targeted CAR-T therapy, leading to decreased tumor growth and the extended survival period of mice [130]. The gene discussed is CA9; the disease is neoplasm.